Article

Multifocal ablations for presbyopia explored

Las Vegas-Customized multifocal ablations, used to correct both hyperopia and presbyopia, appear to offer good results for both uncorrected distance and near vision and may provide another option for surgeons and their patients, said Marguerite B. McDonald, MD, FACS, at the American Academy of Ophthalmology annual meeting.

She presented 1-year outcomes from the Canadian trial lead by W. Bruce Jackson, MD, professor and chairman of ophthalmology, University of Ottawa, Ontario, Canada, of 43 hyperopic presbyopic patients (75 eyes) treated with customized bilateral ablations. In addition, the 6-month U.S. clinical trial results of 20 patients (20 eyes), treating the dominant eye for distance and the non-dominant eye with a multifocal ablation, were also encouraging. Colman R. Kraff, MD, director of refractive surgery, Kraff Eye Institute, Chicago, led the U.S. study.

In each study, an excimer laser (VISX S4, Advanced Medical Optics [AMO]) was used to create the multifocal ablation pattern using the pupil centroid shift compensation and iris registration upgrades. The central zone is steepened for near, and the peripheral area is targeted for distance. The treatments were customized both to patients' pupil sizes and to their individual wavefronts.

The Canadian results were very encouraging, with 82% of the eyes (n = 71) achieving a binocular uncorrected near vision of J1 or better and 100% achieving J3 or better at 1 month after refractive surgery. The monocular uncorrected near vision was also measured. At 1 month postop, 68% of the eyes (n = 71) achieved J1 or better vision and 92% were J3 or better, Dr. McDonald noted.

Manifest refraction was followed for 1 year postoperatively. Preoperative manifest refraction spherical equivalent (MRSE) was +1.91 ± 0.59 D and dropped to –0.19 ± 0.71 D at 1 month postop. At 1 year after surgery, the MRSE measured +0.12 ± 0.38 D.

"The majority of patients were satisfied with their overall visual sharpness and clarity without [spectacle] correction at 6 and 12 months after surgery," said Dr. McDonald, who is also a clinical professor of ophthalmology, Tulane University Health Sciences Center, New Orleans.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.